{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:28:07Z","timestamp":1786116487742,"version":"build-2736575974"},"reference-count":32,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002462","name":"Chungnam National University","doi-asserted-by":"publisher","award":["2025"],"award-info":[{"award-number":["2025"]}],"id":[{"id":"10.13039\/501100002462","id-type":"DOI","asserted-by":"publisher"}]},{"award":["2025"],"award-info":[{"award-number":["2025"]}],"id":[{"id":"https:\/\/ror.org\/0227as991","id-type":"ROR","asserted-by":"publisher"}]},{"name":"Handok Inc.","award":["2024"],"award-info":[{"award-number":["2024"]}]},{"award":["2024"],"award-info":[{"award-number":["2024"]}],"id":[{"id":"https:\/\/ror.org\/00exehz38","id-type":"ROR","asserted-by":"publisher"}]},{"name":"Korean distributor of teneligliptin"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Sodium\u2013glucose cotransporter-2 (SGLT2) inhibitors provide cardio-renal protection in type 2 diabetes, but tolerability-related discontinuation is common, creating a need for effective replacement therapy. Dipeptidyl peptidase-4 (DPP-4) inhibitors are widely used as follow-on agents, yet the clinical course after such a switch has not been systematically characterized, and whether individual DPP-4 inhibitors differ in efficacy in this setting is unknown. Materials and Methods: We conducted a single-center retrospective cohort study at Chungnam National University Hospital (Daejeon, Republic of Korea) between January 2013 and January 2025, including 117 adults with type 2 diabetes who switched from an SGLT2 inhibitor to a DPP-4 inhibitor and met pre-specified criteria for medication stability and follow-up. The primary outcome was the change in glycated hemoglobin (HbA1c) from baseline to 3 months; secondary outcomes were changes in body weight, body mass index, blood pressure, and renal parameters. A pre-specified subgroup analysis compared teneligliptin (n = 60) with other DPP-4 inhibitors as a class (n = 57). Results: In the overall cohort, body weight rose by 0.7 kg and systolic blood pressure by 4.3 mmHg at 3 months (both p &lt; 0.05), whereas HbA1c was unchanged (p = 0.157). In the subgroup analysis, HbA1c fell significantly with teneligliptin (\u22120.36%; 95% confidence interval, \u22120.62 to \u22120.10; p = 0.009) but not with other DPP-4 inhibitors (+0.13%). The between-group difference was \u22120.49% (95% confidence interval, \u22120.83 to \u22120.15; p = 0.005) and persisted after adjustment for baseline HbA1c and estimated glomerular filtration rate (p = 0.007). Conclusions: Switching preserved overall glycemic control at 3 months but produced modest, anticipated increases in body weight and blood pressure. Teneligliptin was associated with a greater HbA1c reduction than the pooled group of other DPP-4 inhibitors; this association persisted after adjustment for the two available baseline covariates but could not be adjusted for diabetes duration, medication adherence, diabetic complications, or other unmeasured factors. Because confounding by indication and other residual confounding cannot be excluded in this short-term, single-center analysis, this finding is hypothesis-generating only and requires confirmation in adequately powered prospective head-to-head trials. Importantly, this study evaluated only the glucose-lowering effect of the switch; because the cardio-renal protection of SGLT2 inhibition is not reproduced by DPP-4 inhibitors, a DPP-4 inhibitor should be regarded as an unavoidable substitute when an SGLT2 inhibitor cannot be maintained rather than a therapeutically equivalent replacement, and preserved HbA1c at 3 months does not establish clinical equivalence between the two strategies.<\/jats:p>","DOI":"10.3390\/medicina62081511","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T09:46:38Z","timestamp":1786009598000},"page":"1511","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Glycemic Outcomes After Switching from SGLT2 Inhibitors to DPP-4 Inhibitors in Type 2 Diabetes, with a Comparison of Teneligliptin and Other Agents: A Retrospective Cohort Study"],"prefix":"10.3390","volume":"62","author":[{"given":"Joung Youl","family":"Lim","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon 35015, Republic of Korea"},{"name":"Department of Endocrinology and Metabolism, Chungnam National University Hospital, Daejeon 35015, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minchul","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon 35015, Republic of Korea"},{"name":"Department of Endocrinology and Metabolism, Chungnam National University Hospital, Daejeon 35015, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yea Eun","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon 35015, Republic of Korea"},{"name":"Department of Endocrinology and Metabolism, Chungnam National University Hospital, Daejeon 35015, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju Hee","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon 35015, Republic of Korea"},{"name":"Department of Endocrinology and Metabolism, Chungnam National University Hospital, Daejeon 35015, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6760-4963","authenticated-orcid":false,"given":"Hyun Jin","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon 35015, Republic of Korea"},{"name":"Department of Endocrinology and Metabolism, Chungnam National University Hospital, Daejeon 35015, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyong Hye","family":"Joung","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon 35015, Republic of Korea"},{"name":"Department of Endocrinology and Metabolism, Chungnam National University Sejong Hospital, Sejong 30099, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3414-8949","authenticated-orcid":false,"given":"Bon Jeong","family":"Ku","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon 35015, Republic of Korea"},{"name":"Department of Endocrinology and Metabolism, Chungnam National University Hospital, Daejeon 35015, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0140-6736(24)00537-3","article-title":"Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91)","volume":"404","author":"Adler","year":"2024","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee (2026). 9. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes\u20142026. Diabetes Care, 49, S183\u2013S215.","DOI":"10.2337\/dc26-S009"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1080\/14656566.2020.1817388","article-title":"Real-world evidence for long-term safety and effectiveness of ipragliflozin in Japanese patients with type 2 diabetes mellitus: Final results of a 3-year post-marketing surveillance study (STELLA-LONG TERM)","volume":"22","author":"Nakamura","year":"2021","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Bak, M., Chi, S.A., Jeon, K., Kim, H., Cho, H., Lee, H.S., and Park, K.M. (2024). Discontinuation rates, clinical effects and provocation factors of SGLT-2 inhibitor in the real world. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-71231-7"},{"key":"ref_9","first-page":"68","article-title":"Clinical safety and tolerability of vildagliptin\u2014Insights from randomised trials, observational studies and post-marketing surveillance","volume":"13","author":"Mathieu","year":"2017","journal-title":"Eur. Endocrinol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Nishimura, R., Kato, H., Kisanuki, K., Oh, A., Onishi, Y., Hasegawa, Y., Cai, Z., Tajima, Y., and Aoyama, N. (2019). Treatment patterns, persistence and adherence rates in patients with type 2 diabetes mellitus in Japan: A claims-based cohort study. BMJ Open, 9.","DOI":"10.1136\/bmjopen-2018-025806"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/s41574-020-0399-8","article-title":"Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus","volume":"16","author":"Deacon","year":"2020","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.diabet.2014.07.004","article-title":"Efficacy of vildagliptin and sitagliptin in lowering fasting plasma glucose: Results of a randomized controlled trial","volume":"41","author":"Eschenbach","year":"2015","journal-title":"Diabetes Metab."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Morimoto, T., Sakuma, I., Sakuma, M., Tanaka, A., Node, K., Otsuka, Y., Yokoyama, K., Yokota, Y., Iwakura, K., and Kasai, T. (2019). Randomized Evaluation of Anagliptin vs Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) trial: A 52-week, open-label, randomized clinical trial. Sci. Rep., 9.","DOI":"10.1038\/s41598-019-44885-x"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Tang, Y.Z., Wang, G., Jiang, Z.H., Yan, T.T., Chen, Y.J., Yang, M., Meng, L.C., Zhu, Y.J., Li, C.G., and Li, Z. (2015). Efficacy and safety of vildagliptin, sitagliptin, and linagliptin as add-on therapy in Chinese patients with T2DM inadequately controlled with dual combination of insulin and traditional oral hypoglycaemic agent. Diabetol. Metab. Syndr., 7.","DOI":"10.1186\/s13098-015-0087-3"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.metabol.2014.08.006","article-title":"Dipeptidyl peptidase-4 inhibitor, vildagliptin, inhibits pancreatic beta cell apoptosis in association with its effects suppressing endoplasmic reticulum stress in db\/db mice","volume":"64","author":"Wu","year":"2015","journal-title":"Metabolism"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.numecd.2014.01.017","article-title":"Dipeptidyl peptidase-4 inhibitors and heart failure: A meta-analysis of randomized clinical trials","volume":"24","author":"Monami","year":"2014","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/cpdd.29","article-title":"Pharmacokinetics of teneligliptin in subjects with renal impairment","volume":"2","author":"Halabi","year":"2013","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.metabol.2015.10.030","article-title":"A novel DPP-4 inhibitor teneligliptin scavenges hydroxyl radicals: In vitro study evaluated by electron spin resonance spectroscopy and in vivo study using DPP-4 deficient rats","volume":"65","author":"Kimura","year":"2016","journal-title":"Metabolism"},{"key":"ref_19","unstructured":"Korea, I.Q.V.I.A. (2026). UBIST (Ubist Pharmaceutical Information System) Nationwide Pharmaceutical Market Research Database, IQVIA Korea. Available online: https:\/\/www.iqvia.com\/locations\/korea."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Sagara, M., Suzuki, K., Aoki, C., Tanaka, S., Taguchi, I., Inoue, T., and Aso, Y. (2016). Impact of teneligliptin on oxidative stress and endothelial function in type 2 diabetes patients with chronic kidney disease: A case\u2013control study. Cardiovasc. Diabetol., 15.","DOI":"10.1186\/s12933-016-0396-3"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13300-014-0061-3","article-title":"Comparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: A systematic review and mixed treatment comparison","volume":"5","author":"Craddy","year":"2014","journal-title":"Diabetes Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"417","DOI":"10.4093\/dmj.2022.0106","article-title":"Diabetes fact sheet in Korea 2021","volume":"46","author":"Bae","year":"2022","journal-title":"Diabetes Metab. J."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jama.2018.18269","article-title":"Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: The CARMELINA randomized clinical trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0167-0115(03)00111-3","article-title":"Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects","volume":"114","author":"Krarup","year":"2003","journal-title":"Regul. Pept."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1007\/s13300-021-01148-1","article-title":"Efficacy and safety of switching to teneligliptin in patients with type 2 diabetes inadequately controlled with dipeptidyl peptidase-4 inhibitors: 52-week results from a prospective observational study","volume":"12","author":"Kim","year":"2021","journal-title":"Diabetes Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1161\/CIRCULATIONAHA.118.038352","article-title":"Linagliptin effects on heart failure and related outcomes in individuals with type 2 diabetes mellitus at high cardiovascular and renal risk in CARMELINA","volume":"139","author":"McGuire","year":"2019","journal-title":"Circulation"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s12020-016-1052-0","article-title":"The dipeptidyl peptidase-4 (DPP-4) inhibitor teneligliptin functions as antioxidant on human endothelial cells exposed to chronic hyperglycemia and metabolic high-glucose memory","volume":"56","author":"Pujadas","year":"2017","journal-title":"Endocrine"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.bbrc.2013.03.010","article-title":"A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site","volume":"434","author":"Nabeno","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.biopha.2018.10.016","article-title":"Teneligliptin protects against hypoxia\/reoxygenation-induced endothelial cell injury","volume":"109","author":"Zhang","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/dom.13566","article-title":"Teneligliptin versus sitagliptin in Korean patients with type 2 diabetes inadequately controlled with metformin and glimepiride: A randomized, double-blind, non-inferiority trial","volume":"21","author":"Kim","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7888\/juoeh.40.1","article-title":"Comparison of the effects of teneligliptin and sitagliptin, two dipeptidyl peptidase 4 inhibitors with different half-lives, on glucose fluctuation and glucagon-like peptide-1 in type 2 diabetes mellitus","volume":"40","author":"Kurozumi","year":"2018","journal-title":"J. UOEH"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jamainternmed.2018.6551","article-title":"Comparing automated office blood pressure readings with other methods of blood pressure measurement for identifying patients with possible hypertension: A systematic review and meta-analysis","volume":"179","author":"Roerecke","year":"2019","journal-title":"JAMA Intern. Med."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/8\/1511\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T10:29:21Z","timestamp":1786012161000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/8\/1511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":32,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["medicina62081511"],"URL":"https:\/\/doi.org\/10.3390\/medicina62081511","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]}}}